Dear XXXXXX
The company has not yet released any trial results from the mid-dose patients. We previously disclosed all of the low-dose patients were treated.
In my opinion (top priority), Oncolix needs to address the principal note payments that are due commencing in May of this year. Oncolix is working diligently to resolve this issue and I am confident it will be addressed.
Michael
From: XXXXXXXX
Sent: Saturday, April 14, 2018 6:03 PM
To: Michael T. Redman
Subject: stock price
Mr. Redman ,
I am writing to you as a share holder , disappointment is all I can say about the management's silence as the stock price plummets. Please give up some information on the trials . Have any patient been given the drug ,how many?
